Nektar Therape…
ProfileJobs

Nektar Therapeutics

Suggest Edit
    • Healthbiotechdrug developmentoncologypharma

    Nektar Therapeutics is a stage-clinical biopharmaceutical company. The Сompany develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify the chemical structure of substances. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. Nektar Therapeuticsэ R&D pipeline of new investigational drugs includes treatments for cancer, auto-immune disease, and chronic pain.

    Revenue(FY, 2017)
    $307.7 M
    Market capitalization(2018-07-18)
    $8.2 B
    Type
    Public
    HQ
    San Francisco, US
    Founded
    1990
    Size (employees)
    468 (est)
    Website
    nektar.com
    Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, US
    Report incorrect company information

    Key People/Management at Nektar Therapeutics

    Robert Chess

    Robert Chess

    Chairman of the Board
    Jillian Thomsen

    Jillian Thomsen

    Senior Vice President, Finance and Chief Accounting Officer
    Dorian Hirth

    Dorian Hirth

    Senior Vice President, Human Resources and Facilities Operations
    Timothy Riley

    Timothy Riley

    Senior Vice President, Technology Assessment and Quality Assurance
    Show more

    Nektar Therapeutics Office Locations

    Nektar Therapeutics has offices in San Francisco, Huntsville and Hyderabad
    San Francisco, US (HQ)
    455 Mission Bay Boulevard South
    Huntsville, US
    1112 Church Street
    Hyderabad, IN
    Sy.Nos.101/2 Genome Valley Lalgadi Malakpet Shameerpet Mandal Rangareddy District Hyderabad
    Show all (3)
    Report incorrect company information

    Nektar Therapeutics Financials and Metrics

    Nektar Therapeutics Revenue

    Embed Graph
    Nektar Therapeutics's revenue was reported to be $307.71 m in FY, 2017
    USD

    Revenue (Q1, 2018)

    		38 m

    Gross profit (Q1, 2018)

    		31.4 m

    Gross profit margin (Q1, 2018), %

    		82.5%

    Net income (Q1, 2018)

    		(95.8 m)

    EBIT (Q1, 2018)

    		(86.7 m)

    Market capitalization (18-Jul-2018)

    		8.2 b

    Closing share price (18-Jul-2018)

    		47.9

    Cash (31-Mar-2018)

    		34.8 m
    Nektar Therapeutics's current market capitalization is $8.2 b.
    Annual
    USDFY, 2013FY, 2014Y, 2015FY, 2016FY, 2017

    Revenue

    		148.9 m200.7 m230.8 m165.4 m307.7 m

    Revenue growth, %

    		35%15%(28%)

    Cost of goods sold

    		38.5 m28.5 m34.1 m30.2 m30.5 m

    Gross profit

    		110.4 m172.2 m196.7 m135.2 m277.2 m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

    Revenue

    		60.9 m19.8 m28.5 m132.9 m108.8 m22.7 m60 m58.9 m32.8 m36.3 m24.7 m34.6 m38 m

    Cost of goods sold

    		12.9 m7.9 m5.1 m9.2 m8.4 m10.5 m6.8 m8.9 m7.7 m7 m6.1 m9 m6.6 m

    Gross profit

    		48 m11.9 m23.4 m123.7 m100.4 m12.1 m53.2 m50 m25.1 m29.3 m18.6 m25.6 m31.4 m

    Gross profit Margin, %

    		79%60%82%93%92%54%89%85%76%81%75%74%83%
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Cash

    		39.1 m12.4 m55.6 m59.6 m4.8 m

    Accounts Receivable

    Inventories

    		13.5 m13 m11.3 m11.1 m10.7 m

    Current Assets

    		257.9 m288.2 m350.1 m426.3 m326.8 m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

    Cash

    		65.4 m32.4 m30.7 m32 m129.5 m20.9 m18.8 m72.5 m55.7 m63.3 m23.5 m16.1 m34.8 m

    Accounts Receivable

    		4.6 m1.9 m3 m46.1 m2.9 m3.7 m3 m39.7 m27.8 m14.2 m1.6 m4.1 m15.6 m

    Inventories

    		15.1 m12.9 m14.1 m11.7 m12.5 m10.1 m10.4 m11.3 m10.3 m10.8 m13 m11 m10.7 m

    Current Assets

    		207.9 m304.8 m298.2 m324.1 m347.3 m302.2 m286.4 m344.8 m318.3 m282.5 m381 m288.2 m336 m
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Net Income

    		(162 m)(53.9 m)(81.2 m)(153.5 m)(96.7 m)

    Depreciation and Amortization

    		14.3 m12.9 m12.9 m15.4 m14.7 m

    Inventories

    		4.8 m500 k1.6 m237 k383 k

    Accounts Payable

    		6.2 m(6.4 m)(412 k)518 k2.1 m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

    Net Income

    		(16.5 m)(46.2 m)(32.6 m)70.6 m33.8 m(52.7 m)(8.2 m)(19.5 m)(48.6 m)(43.2 m)(63.9 m)(95.8 m)

    Depreciation and Amortization

    		3 m2.5 m

    Inventories

    		14.1 m11.7 m441 k10.1 m10.4 m11.3 m10.3 m10.8 m13 m51 k

    Accounts Payable

    		7.4 m5.4 m2.2 m2.8 m2.3 m2.3 m2.3 m7.1 m7 m6.5 m
    show all
    USDY, 2018

    Financial Leverage

    		8.5 x
    Show all financial metrics
    Report incorrect company information

    Competitors

    CytomX Therapeutics
    Health - Public
    Merrimack Pharmaceuticals
    Health - Public
    Karyopharm Therapeutics
    Health - Subsidiary
    TESARO
    Health - Public
    Compare competitors

    Nektar Therapeutics Online and Social Media Presence

    Embed Graph
    Report incorrect company information

    Nektar Therapeutics News and Updates

    June 26, 2018

    Is Nektar Therapeutics Still A Good Bet Despite The Correction?

    June 12, 2018

    Nektar Therapeutics: In The Midst Of A Difficulty An Opportunity Arises

    June 04, 2018

    Nektar Therapeutics Preliminary Results At ASCO Means A Strong Push Into Phase 3 Studies

    May 16, 2018

    Nektar Therapeutics: Substantial Unlocked Value In The NKTR-358 Franchise

    April 13, 2018

    Nektar Therapeutics: What The REVEAL Study Entails

    Report incorrect company information

    Nektar Therapeutics Company Life and Culture

    Report incorrect company information
    Download PDF